🔎 Trials Near Me

Domov › Alzheimerjeva bolezen › Michigan

Klinične študije za Alzheimerjeva bolezen v Michigan

15 študij za Alzheimerjeva bolezen išče udeležence na lokacijah v Michigan.

Mesta v Michigan

Uradno besedilo študije (angleško)

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  • Local Institution - 1620, Troy
Vključevanje udeležencevFaza 3
Starost 55–90 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06937229

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

  • Quest Research Institute, Farmington Hills
Vključevanje udeležencevFaza 4
Starost 50 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07633470

A Study of LY3439539 in Participants With Alzheimer's Disease

  • QUEST Research Institute, Farmington Hills
Vključevanje udeležencevFaza 1
Starost 50–85 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07598370

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  • QUEST Research Institute, Farmington Hills
Vključevanje udeležencevFaza 2
Starost 55–85 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07589595

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  • Neurobehavioral Medicine Group (NBMG), Bloomfield Township
Vključevanje udeležencevFaza 3
Starost 55–90 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06585787

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  • Quest Research Institute, Farmington Hills
Vključevanje udeležencevFaza 3
Starost 50–90 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07177352

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  • QUEST Research Institute, Farmington Hills
Vključevanje udeležencevFaza 3
Starost 60–85 · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06976203

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  • NeuroBehavioral Medicine Group, Bloomfield Hills
  • Oakland Medical Research, Troy
Vključevanje udeležencevFaza 3
Starost 55–90 · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07011732

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

  • Michigan Medicine, Ann Arbor
Vključevanje udeležencev
Starost 70 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT05929703

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  • Local Institution - 0088, Sterling Heights
Vključevanje udeležencevFaza 2
Starost 55–90 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT06808984

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  • Henry Ford Health System, Detroit
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT06563895

Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial

  • Shiawasee Health Department, Corunna
  • McLaren Flint OB-GYN, Flint
  • Munson Gaylord OB-GYN, Gaylord
  • in še 5
Vključevanje udeležencev
Starost 18 in več · Ženske · Posodobljeno 24. jul. 2026 · NCT07213284

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  • Revival Research Institute, LLC, Southfield
Vključevanje udeležencevFaza 3
Starost 55 in več · Vsi spoli · Posodobljeno 7. jul. 2026 · NCT07602582

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

  • QUEST Research Institute, Farmington Hills
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
Starost 45–85 · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT06657768

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  • Quest Research Institute, Farmington Hills
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 60–90 · Vsi spoli · Posodobljeno 15. apr. 2026 · NCT06584357

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.